Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar. 

 -  2014 
<br/><br/>Available online from MWHC library: 1950 - present, Available in print through MWHC library: 1999 - 2006 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>0009-7322 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Acute Coronary Syndrome/pc [Prevention & Control]<br/>*Drug Approval<br/>*Lactones/tu [Therapeutic Use]<br/>*Plaque, Atherosclerotic/pc [Prevention & Control]<br/>*Platelet Aggregation Inhibitors/tu [Therapeutic Use]<br/>*Pyridines/tu [Therapeutic Use]<br/>Clinical Trials Data Monitoring Committees<br/>Hemorrhage/ep [Epidemiology]<br/>Humans<br/>Lactones/ae [Adverse Effects]<br/>Platelet Aggregation Inhibitors/ae [Adverse Effects]<br/>Pyridines/ae [Adverse Effects]<br/>Receptor, PAR-1/ai [Antagonists & Inhibitors]<br/>Risk Assessment<br/>United States
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Heart & Vascular Institute
<br/><br/><label>Index Terms--Function: </label><br/>Congresses